bimekizumab
Selected indexed studies
- Bimekizumab versus Secukinumab in Plaque Psoriasis. (N Engl J Med, 2021) [PMID:33891380]
- Bimekizumab. (, 2006) [PMID:38051799]
- Bimekizumab versus Adalimumab in Plaque Psoriasis. (N Engl J Med, 2021) [PMID:33891379]
_Worker-drafted node — pending editorial review._
Connections
bimekizumab is a side effect of
Sources
- Bimekizumab versus Adalimumab in Plaque Psoriasis. (2021) pubmed
- Bimekizumab versus Secukinumab in Plaque Psoriasis. (2021) pubmed
- Bimekizumab. (2006) pubmed
- Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. (2024) pubmed
- Bimekizumab for the treatment of psoriasis. (2024) pubmed
- Bimekizumab-bkzx. (2024) pubmed
- Bimekizumab (Bimzelx®). (1994) pubmed
- Bimekizumab (Bimzelx®). (1994) pubmed
- Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). (2023) pubmed
- Bimekizumab for the treatment of psoriatic arthritis. (2024) pubmed